NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor, Gansu Provincial Hospital, Lanzhou, 730000, China; The Institute of Clinical Research and Translational Medicine, Gansu Provincial Hospital, Lanzhou, 730000, China.
NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor, Gansu Provincial Hospital, Lanzhou, 730000, China; The Institute of Clinical Research and Translational Medicine, Gansu Provincial Hospital, Lanzhou, 730000, China.
Nutr Metab Cardiovasc Dis. 2021 Jan 4;31(1):169-177. doi: 10.1016/j.numecd.2020.07.045. Epub 2020 Aug 7.
Serum pepsinogens (PGs) are biomarkers for gastric mucosal damage and have been reported to be associated with atherosclerosis. Its correlation with atherosclerotic cardiovascular disease (ASCVD) is still unknown. This study aimed to explore the association between serum PGs and ASCVD for providing physicians with an integrative picture to make rational plans in the diagnosis and treatment of ASCVD.
The concentrations of serum PGs and their distributions between ASCVD and non-ASCVD were compared by non-parametric test, Chi-squared test and Fisher exact test. The correlation between variables was analyzed by Spearman's correlation test. The association of serum PGs with ASCVD was analyzed by the binary logistic regression and two-piecewise linear regression. A total of 8355 recruited cases were eligible for the study. The concentrations of serum PGs were significantly different between the ASCVD and non-ASCVD groups (P = 0.025, P < 0.001). The lower PGI and PGR levels were significantly correlated with a high risk of ASCVD presence after adjustment for 26 potential covariates. Moreover, there was a linear relationship between the high level of PGII and the high risk of ASCVD [adjusted OR = 1.16 (1.00, 1.37), P = 0.07]. A nonlinear relationship of PGI/PGR and ASCVD (P = 0.08/<0.001) was also revealed. The risk of ASCVD increased with a range of log PGI ≥2.13 (PGI≥131 ng/mL) [adjusted OR = 4.67 (1.00, 23.17)], and decreased with a range of log PGR ≥0.22 (1.65) [adjusted OR = 0.59 (0.48, 0.74), P < 0.001].
Serum PGI and PGR are nonlinearly correlated with ASCVD, while PGII is linearly correlated with ASCVD. Among all PGs, PGR may serve as a reliable biomarker for ASCVD.
血清胃蛋白酶原(PGs)是胃黏膜损伤的生物标志物,已有研究表明其与动脉粥样硬化相关。但其与动脉粥样硬化性心血管疾病(ASCVD)的相关性尚不清楚。本研究旨在探讨血清 PGs 与 ASCVD 的相关性,为临床医生提供综合信息,以便在 ASCVD 的诊断和治疗中制定合理的方案。
采用非参数检验、卡方检验和 Fisher 确切概率法比较 ASCVD 组与非 ASCVD 组血清 PGs 浓度及其分布,采用 Spearman 相关分析比较变量间相关性,采用二分类 Logistic 回归和两段线性回归分析血清 PGs 与 ASCVD 的相关性。共纳入 8355 例符合条件的研究对象。ASCVD 组与非 ASCVD 组血清 PGs 浓度差异有统计学意义(P = 0.025,P < 0.001)。校正 26 个潜在混杂因素后,较低的 PGI 和 PGR 水平与 ASCVD 发生的高风险显著相关。此外,PGII 水平升高与 ASCVD 发生的高风险呈线性相关[校正 OR = 1.16(1.00,1.37),P = 0.07]。PGI/PGR 与 ASCVD 之间也存在非线性关系(P = 0.08/<0.001)。PGI≥131 ng/mL[校正 OR = 4.67(1.00,23.17)]和 PGR≥1.65[校正 OR = 0.59(0.48,0.74),P < 0.001]时,ASCVD 风险增加和降低。
血清 PGI 和 PGR 与 ASCVD 呈非线性相关,而 PGII 与 ASCVD 呈线性相关。在所有 PG 中,PGR 可能是 ASCVD 的可靠生物标志物。